ContraFect Corp. Company Profile (NASDAQ:CFRX)

Analyst Ratings

Consensus Ratings for ContraFect Corp. (NASDAQ:CFRX) (?)
Ratings Breakdown: 2 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $5.15 (114.58% upside)

Analysts' Ratings History for ContraFect Corp. (NASDAQ:CFRX)
Show:
DateFirmActionRatingPrice TargetActions
7/28/2016Piper Jaffray Cos.Initiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2016Maxim GroupDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Roth CapitalDowngradeBuy -> Neutral$4.00 -> $3.30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for ContraFect Corp. (NASDAQ:CFRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016($0.25)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.23)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015($0.27)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/7/2015($0.23)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.15)($1.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ContraFect Corp. (NASDAQ:CFRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.26)($0.23)($0.25)
Q2 20162($0.25)($0.23)($0.24)
Q3 20162($0.28)($0.27)($0.28)
Q4 20162($0.29)($0.27)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ContraFect Corp. (NASDAQ:CFRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ContraFect Corp. (NASDAQ:CFRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/27/2016Steven C GilmanCEOBuy20,000$2.48$49,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Daniel CoutoSVPSell2,872$3.81$10,942.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Daniel CoutoSVPSell2,867$4.23$12,127.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/20/2015Daniel CoutoSVPSell2,867$4.48$12,844.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Daniel CoutoSVPSell2,867$4.11$11,783.37View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2015Daniel CoutoSVPSell2,867$4.76$13,646.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Daniel CoutoSVPSell2,867$4.90$14,048.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Julia P GregoryCEOBuy11,778$4.61$54,296.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ContraFect Corp. (NASDAQ:CFRX)
DateHeadline
07/27/16 08:31 AMCONTRAFECT CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements an -
07/22/16 03:12 PMContraFect (CFRX) Prices 14M Common Stock, Warrants Offering for Proceeds of ~$35M
07/22/16 03:12 PMContraFect Corp (NASDAQ:CFRX) Loses Ground On New Stock Offering
07/22/16 01:20 PMCFRX: Company Raises $35 Million; Steven Gilman Appointed as CEO -
07/22/16 10:51 AMContraFect downgraded by Maxim Group -
07/22/16 09:18 AMContraFect Corporation Prices $35 Million Public Offering of Common Stock and Warrants - [at noodls] - YONKERS, NY -- (Marketwired) -- 07/22/16 -- ContraFect Corporation(NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
07/21/16 04:30 PMCONTRAFECT CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors or Principal -
07/21/16 04:29 PMContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer - [Marketwired] - ContraFect Corporation , a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious...
06/27/16 01:30 PMCFRX: New PK/PD and Microbiologic Data Presented on CF-301 -
06/27/16 05:10 AMCONTRAFECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/21/16 06:29 AMContraFect Presents New CF-301 Data at ASM Microbe 2016 - [at noodls] - YONKERS, NY -- (Marketwired) -- 06/21/16 -- ContraFect Corporation(NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
06/21/16 06:01 AM7:01 am ContraFect announces 3 presentations of new data on CF-301 at ASM 2016 -
06/10/16 04:04 PMContraFect Corp. :CFRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/08/16 06:08 AMContraFect Announces Presentation of Data at ASM Microbe 2016 - [at noodls] - YONKERS, NY -- (Marketwired) -- 06/08/16 -- ContraFect Corporation(NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
06/01/16 06:23 AMContraFect to Present at Jefferies 2016 Healthcare Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 06/01/16 -- ContraFect Corporation(NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
05/17/16 11:45 AMCFRX: Phase 2 Trial of CF-301 in Bacteremia Patients to Commence in 4Q16 -
05/10/16 03:15 PMCONTRAFECT CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Ma -
05/10/16 06:28 AMContraFect Announces First Quarter 2016 Results - [at noodls] - YONKERS, NY -- (Marketwired) -- 05/10/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
05/10/16 06:07 AMQ1 2016 ContraFect Corp Earnings Release - Time Not Supplied -
05/03/16 06:10 AMContraFect Corporation to Announce First Quarter 2016 Results on May 10, 2016 - [at noodls] - YONKERS, NY -- (Marketwired) -- 05/03/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics ...
04/12/16 12:35 PMCFRX: CF-301 Phase 1 Results Presented at ECCMID Conference -
04/12/16 05:03 AMCONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers -
04/01/16 07:46 AMKeryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors - [at noodls] - BOSTON, April 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today ...
04/01/16 07:46 AMKeryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors - [at noodls] - BOSTON, April 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today ...
03/29/16 06:24 AMContraFect to Present CF-301 Phase 1 Trial Data at the 26th ECCMID Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 03/29/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
03/29/16 06:24 AMContraFect to Present CF-301 Phase 1 Trial Data at the 26th ECCMID Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 03/29/16 -- ContraFect Corporation (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for ...
02/26/16 01:15 PMStocks With High Analyst Interest: The Spectranetics Corporation (NASDAQ:SPNC), Euronet Worldwide, Inc. (NASDAQ ... - RiversideGazette.com - Stocks With High Analyst Interest: The Spectranetics Corporation (NASDAQ:SPNC), Euronet Worldwide, Inc. (NASDAQ ...RiversideGazette.comShares of ContraFect Corporation (NASDAQ:CFRX) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $11.00 price target according to the covering analysts.
02/26/16 01:15 PMChanges To Broker Targets On ContraFect Corporation (CFRX) - Share Trading News - Changes To Broker Targets On ContraFect Corporation (CFRX)Share Trading NewsThe share price of ContraFect Corporation (CFRX) was down -4.52% during the last trading session, with a day high of 3.27. 18084 shares were traded on ContraFect Corporation's last session. The stock's 50 day moving average is 3.61 and its 200 day ...
02/02/16 06:00 AMContraFect to Present at 18th Annual BIO CEO and Investor Conference - [Marketwired] - ContraFect Corporation , a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced...
01/20/16 04:26 PMCONTRAFECT CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
01/05/16 06:38 AMContraFect to Present at 8th Annual Biotech Showcase Conference - [at noodls] - -- () -- -- (NASDAQ: CFRX)(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious ...
12/16/15 03:30 PMCFRX: Phase 1 Study of CF-301 Complete with No Clinical Adverse Safety Signals Found; Increasing PT to $12 -
12/15/15 06:16 AMContraFect Corporation Concludes Phase 1 Study of CF-301 - [at noodls] - -- () -- -- (NASDAQ: CFRX)(NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant ...
12/08/15 12:17 PMCONTRAFECT CORP Financials -
11/30/15 03:55 PMContraFect to Present at 27th Annual Piper Jaffray Healthcare Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 11/30/15 -- ContraFect Corporation(NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products ...
11/18/15 01:00 PMCFRX: Warrant Exercise Brings in $9.6 Million; Data From Phase 1 Study of CF-301 in 1H2016… -
11/12/15 05:45 PMContraFect reports 3Q loss -
11/12/15 05:23 PMCONTRAFECT CORP Files SEC form 10-Q, Quarterly Report -
11/12/15 05:16 PMContraFect Corporation Announces Third Quarter 2015 Financial and Operating Results - [at noodls] - YONKERS, NY -- (Marketwired) -- 11/12/15 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) FDA Fast Track Designation Granted to CF-301, currently in Phase 1 clinical trials for Staph bacteremia, ...

Social

About ContraFect Corp.

ContraFect Corp. logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CFRX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.40
  • 50 Day Moving Average: $2.76
  • 200 Day Moving Average: $3.20
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $65.96M
  • Beta: -0.99
  • Current Year EPS Consensus Estimate: $-1.13 EPS
  • Next Year EPS Consensus Estimate: $-1 EPS
Additional Links:
ContraFect Corp. (NASDAQ:CFRX) Chart for Saturday, July, 30, 2016